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Abstract
More than 40 years have passed since Kawasaki syndrome (KS) was first described. Yet KS still remains an enigmatic
illness which damages the coronary arteries in a quarter of untreated patients and is the most common cause of
childhood-acquired heart disease in developed countries. Many gaps exist in our knowledge of the etiology and
pathogenesis of KS, making improvements in therapy difficult. In addition, many KS features and issues still
demand further efforts to achieve a much better understanding of the disease. Some of these problem areas
include coronary artery injuries in children not fulfilling the classic diagnostic criteria, genetic predisposition to KS,
unpredictable ineffectiveness of current therapy in some cases, vascular dysfunction in patients not showing
echocardiographic evidence of coronary artery abnormalities in the acute phase of KS, and risk of potential
premature atherosclerosis. Also, the lack of specific laboratory tests for early identification of the atypical and
incomplete cases, especially in infants, is one of the main obstacles to beginning treatment early and thereby
decreasing the incidence of cardiovascular involvement. Transthoracic echocardiography remains the gold-standard
for evaluation of coronary arteries in the acute phase and follow-up. In KS patients with severe vascular
complications, more costly and potentially invasive investigations such as coronary CT angiography and MRI may
be necessary. As children with KS with or without heart involvement become adolescents and adults, the
recognition and treatment of the potential long term sequelae become crucial, requiring that rheumatologists,
infectious disease specialists, and cardiologists cooperate to develop specific guidelines for a proper evaluation and
management of these patients. More education is needed for physicians and other professionals about how to
recognize the long-term impact of systemic problems related to KS.
Background
Kawasaki syndrome (KS, OMIM 611775) is an acute
necrotizing vasculitis of the medium and small-sized
vessels, predominantly occurring in children aged 6
months-5 years, with a male-to-female ratio of 1.5-1.8
to 1 and a life-threatening predisposition to involve cor-
onary arteries [1]. Though damage of coronary arteries
is the main complication of the disease, systemic inflam-
mation in many organs including myocardium, liver,
lungs or kidney has been documented [2]. KS is the
most severe vasculitic syndrome of childhood, typically
striking children younger than age 5, but even observed
in neonates, adolescents and adults [3-5], and nowadays
represents the leading cause of acquired heart disease in
children living in the developed countries, where it has
surpassed rheumatic fever [6]. The peak age in Japan,
where the disease is most common, is 5 to 11 months,
while in the United States it is between 1 and 2 years of
age [7]. As specific laboratory tests are unavailable, the
diagnosis of KS still relies on the clinical criteria
described by Kawasaki himself and listed in Table 1:
fever lasting at least 5 days and four of the five typical
features are required to meet the clinical diagnosis [8].
Mucous-membrane changes are the most frequent man-
ifestations of KS, occurring in more than 90% of
patients, whilst the least frequently observed criterion is
cervical lymphadenopathy. In very young children diag-
nosis is still a challenge for general practitioners, since
the disease’s course is often incomplete and more diffi-
cult to recognize, with subsequent delay of appropriate
therapy and possible increased risk of coronary artery
aneurysms (CAA) [9]. * Correspondence: falcini@unifi.it
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Although reported all over the world, KS is most highly
expressed among Asian populations, mainly of Japanese
and Korean descent. In Japan, the 20th nationwide sur-
vey documented an annual incidence of 216.9 per
100,000 children aged 0-4 years. This incidence is
remarkably greater than in Europe (2.9 to 6.9 cases per
100,000) or in the Caucasian population of the United
States of America (6 to 9 cases per 100,000), supporting
the speculation that both genetic predisposition and
environmental factors are critical for KS pathogenesis
[10]. As emerged from different surveys over different
countries, the disease affects mainly children under 5
years, with a peak incidence in children 1 to 2 years of
age. In addition, siblings of patients with KS have a sig-
nificantly greater chance of acquiring KS than children
in the general population. In Japan siblings of an index
case have a 10-fold increased relative risk of KS. These
familial cases may imply a risk for increased severity or
recurrence of the KS, which varies according to ethnici-
ties, being about 3% in Japan and 0.8% in the States
[11,12]. A host of data show that cardiac sequelae occur
more frequently after a recurrent disease than in the
first episode. Furthermore, patients with a history of
parental KS are prone to develop a more aggressive
course, requiring additional treatment with intravenous
immunoglobulins (IVIG), and have a higher incidence of
cardiac complications [13].
The etiopathogenetic studies in progress
Though many etiological agents have been proposed, the
exact cause of KS continues to be elusive. The rarity of
the illness in the first months of life suggests a passive
protection by maternal antibodies. Seasonality of cases,
nationwide epidemics, and the self limited nature of KS
favor an infectious trigger. Although the subject is still
much debated, current research appears to indicate that
the primum movens of KS might be an infectious agent
with superantigenic activity, leading to a massive stimu-
lation of the immune system and to the development of
KS in a small subset of genetically predisposed indivi-
duals [14]. The discovery of viral-like cytoplasmic inclu-
sion bodies in ciliated bronchial epithelial cells supports
the hypothesis that KS might arise from a previously
unidentified ubiquitous RNA virus giving rise to a state
of persistent viral infection [15].
The immune response in KS encompasses both
aspects of innate and adaptive immunity with a signifi-
cant overproduction of different cytokines and activation
of endothelial cells. Activation of both B and T cells has
been detected together with increased proinflammatory
cytokine production, including tumour necrosis factor
(TNF)-a, interleukin-1 and interleukin-6 [16,17]. The
exact mechanisms leading from immune activation to
localized coronary artery damage are still not elucidated,
but considerable evidence has accumulated in the last
decade to suggest that T cells play a significant role.
Interferon-gamma, a pleiotropic cytokine predominantly
produced by T and NK cells, has been shown to regu-
late the immune response during the development of
Lactobacillus casei cell wall extract-induced coronary
arteritis, an animal model of KS [18]. Many studies have
attempted to identify possible genetic variants in the
major histocompatibility complex region that are asso-
ciated with KS and development of CAA in various
populations, with conflicting results [19,20]. Recently, a
functional single nucleotide polymorphism in the inosi-
tol 1,4,5-trisphosphate 3-kinase C gene, a negative regu-
lator of T cell activation, has been linked to KS
susceptibility in both Japanese and American children
[21]. Genetic variations in the pathway of transforming
growth factor-b, a crucial peptide with regulatory func-
tions in T-cell activation and cardiovascular remodeling,
have been proven to influence KS susceptibility, disease
outcome, and response to therapy [22].
Genome-wide association studies have been performed
to identify novel loci modulating the susceptibility to KS
and plausible candidate gene associations have been
recognized, including apoptosis regulatory genes, genes
implicated in the synthesis of transcription factors and
interleukin inhibitors [23]. A recent study performed in
186 Korean patients has detected two susceptibility loci,
one in the 1p31 region for uncomplicated KS and a sec-
ond in the 2p13.3 region for KS complicated by CAA
[24].
Atypical and incomplete variants of the syndrome
Diagnosing and treating both “atypical” and “incom-
plete” forms of KS remain major dilemmas for clinicians
evaluating children, especially infants, with prolonged or
refractory high fever. Even after 5 years of age, the diag-
nosis of KS can be very hard to establish. According to
Table 1 Clinical findings useful for the diagnosis of classic Kawasaki syndrome: patients with fever lasting more than
five days and refractory to antibiotics must have 4 of the following 5 signs
Polymorphous erythematous rash
Bilateral conjunctival injection without exudate
Changes in oral cavity and lips, including diffuse oropharyngeal hyperemia, strawberry tongue, lip swelling, fissuring, erythema or bleeding
Nonpurulent cervical lymphadenopathy (more than 15 mm in diameter, usually unilateral)
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Academy of Pediatrics, “atypical” KS is defined as a
child with high fever and symptoms and signs heralding
the onset of the disease that are not included in the
clinical major criteria of KS, such as acute abdominal
pain, pulmonary signs, or gastrointestinal signs [25].
The more common atypical signs which can be observed
in KS are listed in Table 2.
Conversely, the term “incomplete” KS refers to
patients who lack the clinical findings of the disease to
fulfill the classic criteria, but present fever, at least two
of the typical clinical manifestations and CAA revealed
by echocardiography [26]. It is clear that the presence of
coronary damage detected by ultrasound investigations
may confirm KS diagnosis in many doubtful cases.
The primary goal for pediatricians should be early
recognition and treatment of both atypical and incom-
plete cases before coronary arteries are damaged.
Among all KS patients, atypical and incomplete cases
have the highest risk of developing CAA if left untreated
with IVIG [27,28]. In children who are suspected to
have KS, acute phase reactants, in particular the erythro-
cyte sedimentation rate (ESR) and C-reactive protein
(CRP), can provide important clues to the diagnosis, as
they are often markedly elevated at least by the fourth
or fifth day of illness, in comparison with levels
expected in children with acute viral illnesses [29].
Laboratory parameters individually have insufficient sen-
sitivity or specificity for a prompt diagnosis; thus, only
the combination of medical history, physical examina-
tion and laboratory tests, including a high white blood
cell count, ESR and CRP, could help in ruling out the
other illnesses. (See Table 3 for a differential diagnosis
o fK S )[ 3 0 ] .S y s t e m i co n s e t - j u v e n i l ei d i o p a t h i ca r t h r i t i s
may also resemble KS both in clinical manifestations
and laboratory abnormalities [31]. Notably, a study of
patients referred for the evaluation of a possible KS
showed that over 40% of children with an alternative
diagnosis simultaneously fulfilled the diagnostic criteria
of KS [32]. Hence, atypical and incomplete KS raise cri-
ticism about the validity and suitability of diagnosis
based on the classic clinical criteria. These patients with
incomplete forms of the disease present not only the
coronary artery involvement, but these children may
also clinically display noncoronary cardiac lesions, such
as pancarditis, conduction system abnormalities, and
subclinical ventricular dysfunction or subtle ventricular
dilations, all involvements possibly independent of CAA
[33].
Another suggestive symptom in recognizing KS is the
extreme irritability of the majority of pediatric patients,
which is mainly related to aseptic meningitis and is
uncommon in other febrile diseases [34]. An interesting
finding, due to the crossreactivity of T-cells between
epitopes of mycobacterial and human heat shock pro-
teins, is the development of erythema and induration at
sites of bacillus Calmette-Guérin immunization: in
countries where anti-tubercular vaccination is common
this sign might aid the clinician in the diagnosis of KS
[35].
Therapy of primary Kawasaki syndrome
Since no criteria have been developed that can reliably
identify children at higher risk for severe disease at the
time of initial presentation, all children diagnosed with
KS must be treated at the time of diagnosis. Since both
KS etiology and pathogenesis are not completely clari-
fied, the general aims of treatment are to rapidly dimin-
ish the inflammation within the vascular system and
specifically in the coronary arteries, minimize the inci-
dence and progression of CAA, and prevent arterial
thrombosis by inhibiting platelet aggregation [36]. The
current treatment strategy is based on IVIG therapy (2
g/kg of body weight in a 10-12 hour-infusion) and
aspirin (50-100 mg/kg daily, divided in four doses), both
Table 2 Atypical findings of Kawasaki syndrome
Neurologic: stiff neck secondary to aseptic meningitis, facial nerve palsy,
sensorineural hearing loss, extreme irritability
Renal: sterile pyuria, proteinuria, nephritis, acute renal failure
Musculo-skeletal: joint involvement (arthralgias or arthritis), leukocytosis
in synovial fluid
Pulmonary: pleural effusion, lung infiltration
Gastrointestinal: abdominal pain, diarrhea, hepatitis, obstructive jaundice,
hepatic dysfunction with hypertransaminasemia, gallbladder hydrops,
pancreatitis
Genital: vulvitis, meatitis, urethritis, sterile pyuria
Ophthalmologic: anterior uveitis
Dermatologic: peripheral extremity gangrene, erythema multiforme-like
lesions, erythema or induration at the site of bacillus Calmette-Guérin
vaccination, Raynaud’s phenomenon
Table 3 Disorders to differentiate from Kawasaki
syndrome
Viral infections (e.g. measles, infection by Adenovirus, Enterovirus or
Epstein-Barr virus)
Scarlet fever
Staphylococcal scalded skin syndrome
Toxic shock syndrome
Bacterial cervical lymphadenitis
Drug hypersensitivity reactions
Stevens-Johnson syndrome
Systemic-onset juvenile idiopathic arthritis
Rocky Mountain spotted fever (Rickettsia rickettsii infection)
Leptospirosis
Mercury hypersensitivity reaction
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treatment has an overall systemic antinflammatory effect
in approximately 80% of patients and reduces the aneur-
ysm formation rate to less than 5%.
IVIG and aspirin therapy should be instituted as soon
as possible when KS is diagnosed. If CAA are detected
in a child prior to the child’s fulfilling all KS diagnostic
criteria, treatment with IVIG and aspirin should also be
initiated then. When the KS diagnosis is delayed but
inflammatory parameters are still high, it is however
recommended to treat patients aggressively with IVIG
and aspirin, especially young infants, even though the
efficacy of this early treatment in preventing coronary
artery injuries is uncertain [38]. Approximately 10 to
20% of children fail to respond to IVIG treatment. Sev-
eral variables seem to predict this unresponsiveness, i.e.
low sodium and albumin, neutrophil leukocytosis, low
platelet count, high transaminases and CRP level, the
day of illness at initial treatment, and patient’sa g e
[39,40]. Various studies have shown that the incidence
of CAA is inversely related to IVIG dose and indepen-
dent of the salicylate dose [41]. After the acute phase of
KS, the aspirin dose can be reduced to 3-5 mg/kg once
daily to act as an inhibitor of platelet function and this
is continued for at least 6-8 weeks or longer if echocar-
diography shows CAA [42]. In children with either an
allergy to aspirin or concomitant varicella and influenza
(who may be at risk to develop Reye syndrome), clopi-
drogel (given at a dose of 1 mg/kg per day up to a max-
imum dose of 75 mg/day) might be a potential
substitute [43].
Although corticosteroids are the treatment of choice
in most vasculitides of adulthood, their role as a first-
choice treatment for KS is controversial. A multicenter
prospective randomized trial of corticosteroids in pri-
mary KS showed that the combination of IVIG and cor-
ticosteroids improves clinical course and coronary artery
outcome, without causing side effects [44]. However,
data from Newburger do not show a clear usefulness of
adding a single dose of intravenous methylprednisolone
to the conventional IVIG therapy for the routine pri-
mary treatment [45]. A recent study has detected a high
regression rate of CAA, including giant aneurysms, after
IVIG infusion followed by pulse intravenous methyl-
prednisolone at the dose of 30 mg/kg for three consecu-
tive days [46].
Management of the refractory Kawasaki syndrome
No specific guidelines are available for the management
of refractory KS patients in whom inflammatory para-
meters do not subside and fever persists or recurs 24 to
48 hours after IVIG infusion, with the possible increased
risk of coronary damage. Most of these patients will
respond to a second infusion of IVIG (at the usual dose
of 2 g/kg), but up to one third of non-responders
remain febrile with a persistently high serum CRP level
[47,48]. Because no controlled trials have been per-
formed, there are different therapeutic approaches in
the treatment of refractory KS with thus far contradic-
tory results. Daily high dose-methylprednisolone for a
period of 1-3 days is often used in patients with a recur-
rent disease, as a third dose of IVIG could be both
expensive and unsuccessful, but the exact benefit of
methylprednisolone in the initial treatment of the dis-
ease and treatment of the refractory cases remains
uncertain [49,50]. A combination of an intravenous
bolus of methylprednisolone followed by oral corticos-
teroids progressively tapered until CRP normalization
has also been administered successfully in a small group
of refractory patients [51].
Infliximab, a chimeric mouse-human monoclonal
antibody targeting soluble and membrane-bound TNF-
alpha, has been successfully used in patients refractory
to IVIG and corticosteroids, even with severe coronary
artery involvement, without substantial side effects
[52,53]. Nonetheless, Hirono et al. have highlighted
that this drug reduces the cytokine-mediated inflam-
mation, but does not suppress vascular cellular infiltra-
tion [54]. Another TNF-blocker, etanercept, a fusion
protein combining the TNF receptor-2 with the Fc
component of human immunoglobulin G1, has been
administered immediately after IVIG infusion and then
weekly in 17 patients aged 6 months-5 years (0.4 mg
kg/dose in the first 5 patients, 0.8 mg kg/dose in the
other 12). This etanercept therapy has led to a stable
defervescence and no increase in coronary artery dia-
meter or new coronary artery dilation [55]. Until
future clinical trials will establish the best clinical
option, infliximab and etanercept can be considered as
potential alternative drugs for refractory KS. Other
strategies that have proven successful in accelerating
the resolution of fever in selected cases of aggressive
or resistant disease include cyclosporine, low-dose oral
methotrexate and plasma exchange [56-58]. Patients
with severe coronary artery involvement, mainly those
with giant aneurysms, require long-term anticoagula-
tion therapy to prevent intracoronary thrombus forma-
tion, myocardial ischemia and potential risk of sudden
death. Current recommendations for systemic anticoa-
gulation include the administration of the combination
of aspirin and warfarin that appear to significantly
reduce the incidence of myocardial infarction [59].
Due to problems associated with warfarin use in chil-
dren, such as difficulties in predicting dose response
and safety concerns, other authors have shown that
some advantage might derive from using low molecu-
lar weight heparin, instead of warfarin, without
increasing the risk of thrombosis or bleeding [60].
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The major sequelae of KS, such as CAA leading to
potential occlusion and cardiac ischemia, are dramati-
cally decreased as a significant result of therapy with
IVIG. Coronary artery damage is regarded as the hall-
mark of KS and is the single risk factor that contributes
the most to an increase in the mortality risk of this dis-
ease in any patient [61]. Other cardiovascular complica-
tions include pericardial effusion, myocarditis, valvulitis,
mainly mitral regurgitation, and aneurysms in systemic
arteries [62]. Up to 25% of untreated children will
develop persistent abnormalities in the coronary arteries
with inflammatory cell infiltration of the arterial wall,
destruction of the internal elastic lamina, necrosis of
smooth muscle cells, myointimal proliferation and sub-
sequent occurrence of dilations or aneurysms [63].
Aneurysms are usually classified as saccular,i fa x i a l
and lateral diameters are nearly equal, or fusiform,i f
symmetric dilation with gradual proximal and distal
tapering is seen. When a coronary artery is larger than
normal without a segmental aneurysm, it is considered
“ectatic“. In addition, according to the last American
Heart Association statement, aneurysms can be classi-
fied as “small“ (less than 5 mm internal diameter),
“medium“ (5-8 mm internal diameter) or “giant“ (more
than 8 mm internal diameter) [64].
Abnormal endothelial function might persist for many
years after the resolution of the acute phase of KS, even
in patients without detectable coronary artery damage.
Patients with this abnormal endothelial function might
display subclinical vasculitis many years after KS [65].
Endothelial dysfunction might also be theoretically a key
event in the pathogenesis of premature atherosclerosis,
coronary stiffness, and hypertension in these patients
[66]. Recently, Mitani et al. assessed the coronary plaque
composition and coronary artery morphology of adoles-
cents and young adults long after KS “in vivo” by virtual
histology intravascular ultrasound, comparing these
results with the concomitant coronary angiographic
findings. Atherosclerotic lesions were characterized by a
heterogeneous intimal area, distinct from a purely fibro-
tic area, giving a new insight into the potential role of
atherogenesis in the coronary artery remodeling after KS
[67].
The long-term outcome of adults who have recovered
from KS without CAA is considered excellent, though
longitudinal studies are required before confirming this
speculation. A heart-healthy lifestyle is recommended
for all patients with a history of KS, including avoidance
of smoking, low fat diet, control of blood pressure and
lipid panels, and regular physical activity, unless contra-
indicated [68,69]. Long-term cardiologic assessment and
management of patients with persistent CAA may be
necessary according to the stratified risks listed in
Table 4. Stress tests, computed tomography angiography
(also known as multi-slice computed tomography), and
m a g n e t i cr e s o n a n c ei m a g i n gm a yb eh e l p f u li nt h i s
long-term followup [70,71]. The indication for coronary
revascularization procedures should be considered when
severe occlusions are observed in the main trunk of the
left coronary artery, more than one major coronary
artery or the proximal segment of the descending coron-
ary artery. Cardiac transplantation is indicated for a
small number of patients with KS presenting with severe
Table 4 Cardiovascular risk stratification for patients with Kawasaki syndrome
Risk level Therapy Physical activity Follow-up Invasive testing
I
(no coronary artery
changes)
None beyond first 6-8
weeks
No restrictions beyond first 6-8 weeks Counseling at 5-year-
intervals
None
II
(transient coronary artery
ectasia)
None beyond first 6-8
weeks
No restrictions beyond first 6-8 weeks Counseling at 3-to-5-
year intervals
None
III
(one small medium
coronary artery
aneurysm)
Low-dose aspirin at least
until aneurysm regression
is documented
For patients < 11 years: no restrictions;for
patients of 11-20 years: physical activity
must be guided by stress test and
myocardial perfusion scan; discouraged
contact or high-impact sports
Annual
echocardiogram +
ECG; biannual stress
test and myocardial
perfusion scan
Angiography, if non
invasive tests suggest
ischemia
IV
(≥1 large or giant
coronary artery
aneurysm or multiple
aneurysms without
obstruction)
Long term antiplatelet
therapy and warfarin or
low molecular weight
heparin
Contact or high-impact sports should be
avoided because of risk of bleeding; other
physical activity recommendations must
be guided by stress test and myocardial
perfusion scan
Biannual
echocardiogram +
ECG; annual stress test
and myocardial
perfusion scan
Angiography at 6-12
months after the
disease
V
(coronary artery
obstruction)
Long term low-dose
aspirin, warfarin or low
molecular weight heparin
if giant aneurysms persist
Contact or high-impact sports should be
avoided because of risk of bleeding; other
physical activity recommendations must
be guided by stress test and myocardial
perfusion scan
Biannual
echocardiogram +
ECG; annual stress test
and myocardial
perfusion scan
Angiography is
recommended to
address the best
personalized
therapeutic option
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lesions, for whom interventional procedures are not fea-
sible [72,73].
Vaccinations in children with Kawasaki syndrome
Routine vaccinations are recommended for all indivi-
duals with KS. The schedule for administration of inac-
tivated childhood vaccines should not be interrupted. As
the passively transmitted antibodies in IVIG can block
t h es p e c i f i ci m m u n er e s p o n s e ,i tm a yb en e c e s s a r yt o
reschedule live viral vaccines (essentially measles and
varicella-containing vaccines) to at least 9 months after
IVIG administration. In Japan an interval of 6 to 11
months is recommended between IVIG infusion and
live vaccine administration, but there is no final agree-
ment for IVIG-non responders who received a second
or a third IVIG infusion; if the child’sr i s ko fe x p o s u r e
to measles or varicella is high, the child should be
immunized and then reimmunized at least 11 months
after administration of IVIG [74]. The administration of
the inactivated vaccine for influenza in recovered KS
children is prudent, especially in children still receiving
aspirin. Recent studies evaluating vaccinations side
effects minimize the risk that vaccines trigger KS,
though a few isolated relationships have been reported
for hepatitis B and rotavirus live vaccines [75-77].
Conclusion
Although our understanding of KS has increased enor-
mously and many facts about KS have been elucidated,
numerous dilemmas remain unsolved. The first concern
is the need for the discovery of the causative agent that
may allow more appropriate treatment for affected chil-
dren. Secondly, there is urgency to identify specific
laboratory tests to shorten the gap between the appear-
ance of the first clinical manifestations and the diagno-
sis, with the possibility of reducing the occurrence of
coronary damage or cardiac complications in adulthood.
A critical point is related to infants younger than 3-6
months who frequently display an atypical or incomplete
form of the disease, often sharing signs and symptoms
with other infantile febrile illnesses mimicking KS.
Therefore, it is crucial to perform early transthoracic
echocardiography in all patients with suspected or estab-
lished KS, and introduce the appropriate therapy even in
the absence of all typical findings.
Patients with giant aneurysms require aggressive antic-
oagulation with lifelong follow-up, including stress tests
and multi-slice computed tomography or magnetic reso-
nance imaging. The degree to which KS is a cardiovas-
cular risk factor for progression to atherosclerosis is
under debate and long term evolution and consequences
of the disease are still unknown, despite many efforts of
researchers worldwide. The available data suggest that
all KS patients, including those without CAA, should
remain connected to their medical system, even in their
transition to adult medical care, with the hope that col-
laborative scientific research among various centers will
help define the cause and eventual prevention of the
syndrome and the optimal management of current KS
patients.
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